CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.05 USD | -5.81% |
|
-14.90% | -55.73% |
| 05-15 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CABALETTA BIO, INC. | Bio Therapeutic Drugs | -5.81% | -14.90% | -55.73% | +11.42% | - | 485M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- CABA Stock
- Charts Cabaletta Bio, Inc.
- Comparison Chart
